Fig. 1: Melanoma cell-intrinsic STING activity alone is insufficient for durable tumor control.

Schematic of the STING agonist treatment schedule. Groups of STING^gt/gt mice were injected subcutaneously with 1.5 × 10⁵ B16-ISG or B16-F10 on day 0. On days 5, 8, 10, 12, 14, 16, 18 and 20 following tumor injection, tumor-bearing mice were intratumorally treated with either PBS or 50 μg ADU-S100 (a). Tumor growth curves of B16-ISG (b) and B16-F10 (c) in STING^gt/gt mice treated with PBS control or ADU-S100 as indicated in (a). Data are shown as the mean ± SEM and are representative of two independent experiments. n = 4 and 5 mice in (b) and n = 5 and 6 mice in (c) for ADU-S100 and Control groups, respectively. The frequency of CD8⁺ cells within the CD45⁺ population in B16-ISG (d) and B16-F10 (f) tumors treated with PBS control or ADU-S100 (n = 4 mice per group). Data are shown as mean ± SD and are representative of two independent experiments. Statistical significance was determined by a two-sided t test (ns, not significant). Representative flow cytometry plots for d and f are shown in e and g, respectively.